尽管Her-2阳性乳腺癌具有浸润性强、更容易复发和转移、无病生存期短的特点,但是目前已经有了治疗效果极佳的靶向药物,治疗越早,获益越大。 三阴性乳腺癌(Triple negative Breast cancer,TNBC)的“三阴”是指雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体(Her-2)都没有表达。相比之下,三阴性乳腺癌治疗手...
RESULTS: One hundred eighty-two enrolled patients received ≥1 dose of HER3-DXd. Patients had a median of five previous therapies for advanced disease. Efficacy results are reported across clinical subtypes: hormone receptor-positive (HR+)/human epidermal grow...
[8]Ogden A, Bhattarai S, Sahoo B, et al. Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. Sci Rep. 2020;10(1):3009. [9]Sc...
RESULTS: One hundred eighty-two enrolled patients received ≥1 dose of HER3-DXd. Patients had a median of five previous therapies for advanced disease. Efficacy results are reported across clinical subtypes: hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-neg...
[8]Ogden A, Bhattarai S, Sahoo B, et al. Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. Sci Rep. 2020;10(1):3009. [9]Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortes J, Dieras V, ...
三阴性乳腺癌(triple-negative breast cancer, TNBC)和人表皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)阳性的乳腺癌都是具有高度增殖能力的肿瘤类型,其基因具有不稳定性,可能由于这种基因的不稳定性促使大量肿瘤性抗原暴露在外,促进了抗肿瘤的免疫反应,因此TILs在这些类型的乳腺癌中含量非常高,...
[1]Brasó-Maristany F, Ferrero-Cafiero JM, Falato C, et al. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Nat Commun. 2024;15(1):5826. Published 2024 Jul 11. ...
HER3EGFRBlocking antibodyTargeted therapyPaclitaxelTNBCGROWTH-FACTOR RECEPTORCLINICAL DEVELOPMENTUP-REGULATIONRESISTANCEBackgroundTriple negative breast cancer (TNBC) represents a significant clinical challenge. Chemotherapy remains the mainstay for a large part of TNBC patients, whereas drug resistance and tumor...
antibodies recognize domain I and III of HER3 respectively, blocked HER2-HER3 dimerization and promote HER3 downregulation [173,174,175]. These antibodies, alone or in combination with anti-HER2 therapies, reduced tumor growth in epidermoid, pancreatic, lung, triple-negative breast cancer (TNBC) ...
乳腺癌的治疗决策通常基于传统的组织病理结果,临床上乳腺癌主要分为4种预后不同的亚型:Luminal A型、Luminal B型、人表皮生长因子受体2(human epidermal growth factor receptor 2, HER-2)阳性型和三阴型乳腺癌(triple-negative breast cancer, TNBC)。HER-2是乳腺癌重要的驱动基因和预后指标,也是抗HER-2药物治疗...